Current and future application of genetic toxicity assays: The role and value of in vitro mammalian assays

Toxicological Sciences

Volumn 109, Issue 2, 2009, Pages 172-179

  Elespuru, Rosalie K ^a,b,c   Agarwal, Rajiv ^b,c   Atrakchi, Aisar H ^b,c   Bigger, C Anita H ^b,c   Heflich, Robert H ^b,c,d   Jagannath, Devaraya R ^b,c   Levy, Dan D ^b,c   Moore, Martha M ^b,c,d   Ouyang, Yanli ^b,c   Robison, Timothy W ^b,c   Sotomayor, Rene E ^b,c,g   Cimino, Michael C ^e   Dearfield, Kerry L ^f  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c CDER Genetic Toxicology Subcommittee   (United States)

^d NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^e U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^f U S DEPARTMENT OF AGRICULTURE   (United States)

^g Genetic Toxicology Regulatory and Training Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN;

ARTICLE; CANCER RISK; CARCINOGEN TESTING; CELL ASSAY; CYTOTOXICITY TEST; DNA DAMAGE; GENETIC RISK; GENETIC SCREENING; GENOTOXICITY; HUMAN; IN VITRO STUDY; LYMPHOMA; MUTAGEN TESTING; NONHUMAN; RISK ASSESSMENT;

ANIMALS; CELLS, CULTURED; FALSE POSITIVE REACTIONS; HUMANS; INTERNATIONAL COOPERATION; MAMMALS; MUTAGENICITY TESTS; RATS; RODENTIA;

ANIMALIA; MAMMALIA; RODENTIA;

EID: 66149100452     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp067     Document Type: Article

References (54)

1. Albertini, R. J. (2008). PIG-A as a reporter gene for somatic mutations in humans. Environ. Mol. Mutagen. 49, 539.
2. Applegate, M. L., Moore, M. M., Broder, C. B., Burrell, A., Juhn, G., Kasweck, K. L., Lin, P. F., Wadhams, A., and Hozier, J. C. (1990). Molecular dissection of mutations at the heterozygous thymidine kinase locus in mouse lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 87, 51-55.
3. Aubrecht, J., and Caba, E. (2005). Gene expression profile analysis: An emerging approach to investigate mechanisms of genotoxicity. Pharmacogenomics 6, 419-428.
4. Auletta, A. E., Dearfield, K. L., and Cimino, M. C. (1993). Mutagenicity test schemes and guidelines: US EPA office of pollution prevention and toxics and office of pesticide programs. Environ. Mol. Mutagen. 21, 38-45.
5. Bigger, C. A. H., Moore, M. M., and Heflich, R. H. (2008). In vitro mammalian cell mutation assays. In Preclinical Development Handbook: Toxicology (S. C. Gad, Ed.), pp. 129-153. John Wiley & Sons, Inc., Hoboken, NJ.
6. Cimino, M. C. (2006). Comparative overview of current international strategies and guidelines for genetic toxicology testing for regulatory purposes. Environ. Mol. Mutagen. 47, 362-390.
7. Collins, F. S., Gray, G. M., and Bucher, J. R. (2008). Toxicology: Transforming environmental health protection. Science 319, 906-907.
8. Dearfield, K. L., Auletta, A. E., Cimino, M. C., and Moore, M. M. (1991). Considerations in the U.S. Environmental Protection Agency's testing approach for mutagenicity. Mutat. Res. 258, 259-283.
9. Dearfield, K. L., and Moore, M. M. (2005). Use of genetic toxicology information for risk assessment. Environ. Mol. Mutagen. 46, 236-245.
10. Dertinger, S. D., Miller, R. K., Brewer, K., Smudzin, T., Torous, D. K., Roberts, D. J., Avlasevich, S. L., Bryce, S. M., Sugunan, S., and Chen, Y. (2007). Automated human blood micronucleated reticulocyte measurements for rapid assessment of chromosomal damage. Mutat. Res. 626, 111-119.
11. Elespuru, R. K. (1979). Mutagenicity of nitrosocarbaryl and other methylating nitrosamides as related to uptake in Haemophilus influenzae. Environ. Mutagen. 1, 249-257.
12. U.S. Environmental Protection Agency (EPA). (2005a). Final guidelines for carcinogen risk assessment. Available at: http://cfpub.epa.gov/ncea/ raf/recordisplay.cfm?deid=116283. Accessed September 15, 2005.
13. U.S. Environmental Protection Agency (EPA). (2005b). Supplemental guidance for assessing cancer susceptibility from early-life exposure to carcinogens, EPA/630/P-03/003. Available at: http://cfpub.epa.gov/ncea/ raf/recordisplay.cfm?deid=116283. Accessed September 15, 2005.
14. U.S. Environmental Protection Agency (EPA). (2007). Notice of availability of the external review draft of a "Framework for Determining a Mutagenic Mode of Action for Carcinogenicity: Using EPA's 2005 Cancer Guidelines and Supplemental Guidance for Assessing Susceptibility From Early-Life Exposure to Carcinogens". Fed. Reg. 72(187), 54910-54911. Available at: http://edocket.access.gpo.gov/2007/pdf/E7-19119.pdf. Accessed February 26, 2009.
15. FDA Redbook. (2000). Toxicological Principles for the Safety Assessment of Food Ingredients, Redbook 2000. Available at: http://www.cfsan.fda.gov/-redbook/red-toca.html. Accessed July 2007.
16. Felton, J. S., Knize, M. G., Wu, R. W., Colvin, M. E., Hatch, F. T., and Malfatti, M. A. (2007). Mutagenic potency of food-derived heterocyclic amines. Mutat. Res. 616, 90-94.
17. Fetterman, B. A., Kim, B. S., Margolin, B. H., Schildcrout, J. S., Smith, M. G., Wagner, S. M., and Zeiger, E. (1997). Predicting rodent carcinogenicity from mutagenic potency measured in the Ames Salmonella assay. Environ. Mol. Mutagen. 29, 312-322.
18. Goodman, J. I., Gollapudi, B., and Lehman-McKeeman, L. D. (2007). Genetic toxicity assessment: Employing the best science for human safety evaluation. Toxicol. Sci. 96, 1.
19. Hatch, F. T., Knize, M. G., and Colvin, M. E. (2001). Extended QSAR for 80 aromatic and heterocyclic amines: Structural, electronic and hydropathic factors affecting mutagenic potency. Environ. Mol. Mutagen. 38, 268-291.
20. ICH (International Conference on Harmonization). (2008). Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1). Available at: http://www.ich.org/LOB/ media/MEDIA4474.pdf. Accessed March 6, 2008.
21. Jacobson-Kram, D., and Contrera, J. F. (2007). Genetic toxicity assessment: Employing the best science for human safety evaluation. Part I: Early screening for potential human mutagens. Toxicol. Sci. 96, 16-20.
22. Keshava, C., Chu, M., Cimino, M. C., Dearfield, K. L., Keshava, N., Kligerman, A. D., McCarroll, N. E., Moore, M. M., Owen, R., Putzrath, R. M., et al. (2005). Use of genotoxicity data for determining the mode of action for cancer causing agents. Abstracts of the 9th International Conference on Environmental Mutagens and 36th Annual Meeting of the Environmental Mutagen Society, September 3-8, San Francisco, CA. Mutat. Res. 577S, p. 232.
23. Kirkland, D. J., Aardema, M., Banduhn, N., Carmichael, P., Fautz, R., Meunier, J.-R., and Pfuhler, S. (2007b). In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results. Mutagenesis 22, 161-175.
24. Kirkland, D., Aardema, M., Henderson, L., and Müller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584, 1-256.
25. Kirkland, D., Aardema, M., Müller, L., and Hayashi, M. (2006). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat. Res. 608, 29-42.
26. Kirkland, D. J., Hayashi, M., Jacobson-Kram, D., Kasper, P., MacGregor, J. T., Müller, L., and Uno, Y. (2007c). Summary of major conclusions from the 4th IWGT, San Francisco, 9-10 September, 2005. Mutat. Res. 627, 5-9.
27. Kirkland, D., Pfuhler, S., Tweats, D., Aardema, M., Corvi, R., Darroudi, F., Elhajouji, A., Glatt, H., Hastwell, P., Hayashi, M., et al. (2007a). How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM workshop. Mutat. Res. 628, 31-55.
28. Ku, W. W., Aubrecht, J., Mauthe, R. J., Schiestl, R. H., and Fornace, A. J. (2007). Genetic toxicity assessment: Employing the best science for human safety evaluation. Part VII: Why not start with a single test: A transformational alternative to genotoxicity hazard and risk assessment. Toxicol. Sci. 99, 20-25.
29. Lijinsky, W. (1987). Carcinogenicity and mutagenicity of N-nitroso compounds. Mol. Toxicol. 1, 107-109.
30. Lorge, E., Gervais, V., Becourt-Lhote, N., Maisonneuve, C., Delongeas, J.-L., and Claude, N. (2007b). Genetic toxicity assessment: Employing the best science for human safety evaluation. Part IV: A strategy in genotoxicity testing in drug development: Some examples. Toxicol. Sci. 98, 39-42.
31. Lorge, E., Lambert, C., Gervais, V., Becourt-Lhote, N., Delongeas, J.-L., and Claude, N. (2007a). Genetic toxicity assessment: Employing the best science for human safety evaluation. Part II: Performance of the in vitro micronucleus test compared to the mouse lymphoma assay and the in vitro chromosome aberration assay. Toxicol. Sci. 96, 214-217.
32. McCarroll, N., Keshava, N., Cimino, M., Chu, M., Dearfield, K., Keshava, C., Kligerman, A., Owen, R., Protzel, A., Putzrath, R., et al. (2008). An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide. Environ. Mol. Mutagen. 49, 117-131.
33. Mei, N., Hu, J., Churchwell, M. I., Guo, L., Moore, M. M., Doerge, D. R., and Chen, T. (2008). Genotoxic effects of acrylamide and glycidamide in mouse lymphoma cells. Food Chem. Toxicol. 46, 628-636.
34. Melikian, A. A., Sun, P., Coleman, S., Amin, S., and Hecht, S. S. (1996). Detection of DNA and globin adducts of polynuclear aromatic hydrocarbon diol epoxides by gas chromatography-mass spectrometry and -3H-CH3I postlabeling of released tetraols. Chem. Res. Toxicol. 9, 508-516.
35. +/- mouse lymphoma specific gene and chromosomal mutation assay: A phase III report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 394, 177-303.
36. Miura, D., Dobrovolsky, V. N., Kasahara, Y., Katsuura, Y., and Heflich, R. H. (2008). Development of an in vivo gene mutation assay using the endogenous Pig-A gene: I. Flow cytometric detection of CD59-negative peripheral red blood cells and CD48-negative spleen T-cells from the rat. Environ. Mol. Mutagen. 49, 614-621.
37. Moore, M. M., Honma, M., Clements, J., Bolcsfoldi, G., Burlinson, B., Cifone, M., Clarke, J., Delongchamp, R., Durward, R., Fellows, M., et al. (2006). Mouse lymphoma thymidine kinase gene mutation assay: Follow-up meeting of the International Workshop on Genotoxicity Testing - Aberdeen, Scotland, 2003 - Assay acceptance criteria, positive controls, and data evaluation. Environ. Mol. Mutagen. 47, 1-5.
38. Moore, M. M., Honma, M., Clements, J., Bolcsfoldi, G., Burlinson, B., Cifone, M., Clarke, J., Clay, P., Doppalapudi, R., Fellows, M., et al. (2007). Mouse lymphoma thymidine kinase mutation assay: Meeting of the International Workshop on Genotoxicity Testing. San Francisco, 2005, recommendations for 24-h treatment. Mutat. Res. 627, 36-40.
39. Moore, M. M., Honma, M., Clements, J., Bolcsfoldi, G., Cifone, M., Delongchamp, R., Fellows, M., Gollapudi, B., Jenkinson, P., Kirby, P., et al. (2003). Mouse lymphoma thymidine kinase gene mutation assay: International Workshop on Genotoxicity Tests workgroup report-Plymouth, UK 2002. Mutat. Res. 540, 127-140.
40. Moore, M. M., Honma, M., Clements, J., Harrington-Brock, K., Awogi, T., Bolcsfoldi, G., Cifone, M., Collard, D., Fellows, M., Flanders, K., et al. (2002). Mouse lymphoma thymidine kinase gene mutation assay: Follow-up International Workshop on Genotoxicity Test Procedures, New Orleans, Louisiana, April 2000. Environ. Mol. Mutagen. 40, 292-299.
41. Muehlbauer, P., and Schuler, M. (2003). Measuring the mitotic index in chemically-treated human lymphocyte cultures by flow cytometry. Mutat. Res. 537, 117-130.
42. Muehlbauer, P. A., Spellman, R. A., Gunther, W. C., Sanok, W. E., Wiersch, C. J., O'Lone, S. D., Dobo, K. L., and Schuler, M. J. (2008). Improving dose selection and identification of aneugens in the in vitro chromosome aberration test by integration of flow cytometry-based methods. Environ. Mol. Mutagen. 49, 318-327.
43. Müller, L., Kikuchi, Y., Probst, G., Schechtman, L., Shimada, H., Sofuni, T., and Tweats, D. (1999). ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: Evolution, reasoning and impact. Mutat. Res. 436, 195-225.
44. National Research Council Committee on Toxicity Testing and Assessment of Environmental Agents. (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy.
45. Pfuhler, S., Albertini, S., Fautz, R., Herbold, B., Madle, S., Utesch, D., and Poth, A. (2007). Genetic toxicity assessment: Employing the best science for human safety evaluation. Part IV: Recommendation of a working group of the Gesellschaft fuer Umwelt-Mutationsforschung (GUM) for a simple and straightforward approach to genotoxicity testing. Toxicol. Sci. 97, 237-240.
46. Phonethepswath, S., Bryce, S. M., Bemis, J. C., and Dertinger, S. D. (2008). Erythrocyte-based Pig-a gene mutation assay: Demonstration of cross-species potential. Mutat. Res. 657, 122-126.
47. Pottenger, L. H., Bus, J. S., and Gollapudi, B. B. (2007). Genetic toxicity assessment: Employing the best science for human safety evaluation. Part VI: When salt and sugar and vegetables are positive, how can genotoxicity data serve to inform risk assessment? Toxicol. Sci. 98, 327-331.
48. Sanner, T., and Dybing, E. (2005). Comparison of carcinogenic and in vivo genotoxic potency estimates. Basic Clin. Pharmacol. Toxicol. 96, 131-139.
49. Schildcrout, J. S., Margolin, B. H., and Zeiger, E. (1999). Predicting rodent carcinogenicity using potency measures of the in vitro sister chromatid exchange and chromosome aberration assays. Environ. Mol. Mutagen. 33, 59-64.
50. Tennant, R. W., and Zeiger, E. (1993). Genetic toxicology: Current status of methods of carcinogen identification. Environ. Health. Perspect. 100, 307-315.
51. Thybaud, V., Aardema, M., Casciano, D., Dellarco, V., Embry, M. R., Gollapudi, B. B., Hayashi, M., Holsapple, M. P., Jacobson-Kram, D., Kasper, P., et al. (2007b). Relevance and follow-up of positive results in in vitro genetic toxicity assays: An ILSI-HESI initiative. Mutat. Res. 633, 67-79.
52. Thybaud, V., Aardema, M., Clements, J., Dearfield, K., Galloway, S., Hayashi, M., Jacobson-Kram, D., Kirkland, D., MacGregor, J. T., Marzin, D., et al. (2007a). Strategy for genotoxicity testing: Hazard identification and risk assessment in relation to in vitro testing. Mutat. Res. 627, 41-58.
53. WHO/IPCS (World Health Organisation/International Programme on Chemical Safety). (2007). Draft guidance on mutagenicity testing for chemical risk assessment. Available at: http://www.who.int/ipcs/methods/ harmonization/areas/mutagenicity_testing/en/index.html. Accessed April 17, 2009.
54. Witte, I., Plappert, U., de Wall, H., and Hartmann, A. (2007). Genetic toxicity assessment: Employing the best science for human safety evaluation. Part III: The comet assay as an alternative to in vitro clastogenicity tests for early drug candidate selection. Toxicol. Sci. 97, 21-26.